HCM
SGMO

Highbridge Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Highbridge Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,600
Closed -$387K – 1924
2017
Q3 		$387K Buy
25,600
+6,400
+33% +$70.8K 0.01% 1079
2017
Q2 		$170K Buy
+19,200
New +$123K ﹤0.01% 1135
2015
Q4 		– Sell
-22,000
Closed -$124K – 1775
2015
Q3 		$124K Buy
+22,000
New +$181K ﹤0.01% 1421

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's SGMO Position: Q2 2017 in Review

Highbridge Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2017, closing a stake of 95,287 shares — an estimated $611K sold.

Highbridge Capital Management first reported a position in SGMO in Q3 2013 and held it in 5 quarters. The position peaked at $724K in Q3 2014. 143 funds tracked by Wall St. Rank hold SGMO as of Q2 2017.

  • Highbridge Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 95,287 SANGAMO THERAPEUTICS INC shares in Q2 2017, an estimated $611K.
  • Highbridge Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 5 quarters.
  • Highbridge Capital Management's SANGAMO THERAPEUTICS INC position peaked at $724K in Q3 2014.
  • 143 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.